LH/RH treatment gets double whammy from Medicare law

Why This Topic Matters

The piece helps readers understand why a common prostate cancer treatment workflow was affected by both drug payment reductions and billing rule changes. It is useful for practices evaluating reimbursement impact, coding workflow, and treatment administration options under Medicare policy changes.

Article Sections

1. Medicare payment changes for prostate cancer drug treatment

   Overview of how a new Medicare law and the 2004 fee schedule affected reimbursement for prostate cancer drugs and related administration services. The section frames the payment changes in the context of practice concerns and updated federal policy.

2. Billing and practice response considerations

   Discussion of billing workflow questions, physician work value updates, and operational choices practices considered in response to the reimbursement changes. The section also touches on broader treatment and administration alternatives discussed by practice staff.